Trial Profile

Part 1 of a three part study- A Study to Investigate the Safety, Tolerability and Pharmacokinetics, of AB-729 Administered by Subcutaneous Injection to Healthy Subjects (part 1)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imdusiran (Primary)
Indications Hepatitis B
Focus Adverse reactions; First in man
Sponsors Arbutus Biopharma

Most Recent Events

10 Nov 2021 Results published in an Arbutus Biopharma Media Release
04 Nov 2021 According to an Arbutus Biopharma media release, the company will be presenting data from additional cohorts of this study at the upcoming AASLD medical conference.
02 Nov 2021 Planned End Date changed from 31 Aug 2022 to 2 Jun 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com